Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells

被引:10
作者
Du, Huihui [1 ,2 ]
Wei, Zhiyun [1 ,2 ]
Yan, Yucai [1 ,2 ]
Xiong, Yuyu [1 ,2 ]
Zhang, Xiaoqing [3 ]
Shen, Lu [1 ,2 ]
Ruan, Yunfeng [1 ,2 ]
Wu, Xi [1 ,2 ]
Xu, Qingqing [1 ,2 ]
He, Lin [1 ,2 ,4 ]
Qin, Shengying [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, BioX Inst, Shanghai 200030, Peoples R China
[2] Shanghai Genome Pilot Inst Genom & Human Hlth, Shanghai, Peoples R China
[3] Shanghai Pulm Hosp, Dept Pharm, Shanghai, Peoples R China
[4] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China
关键词
cytochrome P450; genetic polymorphisms; pharmacokinetics; in vitro models; HPLC (high-performance/pressure liquid chromatography); S-warfarin; Chinese Han; HUMAN LIVER-MICROSOMES; IN-VITRO ASSESSMENT; AMINO-ACID; CYTOCHROME-P450; WARFARIN; POPULATION; METABOLISM; POLYMORPHISM; PHENYTOIN;
D O I
10.3389/fphar.2016.00098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Variability in activity of CYP2C9, which is involved in the metabolism of approximately 15% of current therapeutic drugs, is an important contributor to interindividual differences in drug response. To evaluate the functional alternations of CYP2C9*2, CYP2C9*3, CYP2C9*8, CYP2C9*11 and CYP2C9*31, identified in our previous study in Chinese Han population, allelic variants as well as the wild-type CYP2C9 were transiently expressed in COS-7 cells. Kinetic parameters (Km. Vmax, and Clint) for S-warfarin 7-hydroxylation by these recombinant CYP2C9s were determined. Relative to CYP2C9.1, recombinant CYP2C9.3 and CYP2C9.11 exhibited significantly higher Km values, and all allelic variants showed significantly decreased Vmax and Clint values. Among all allelic variants, catalytic activity of CYP2C9.3 and CYP2C9.11 reduced the most (8.2% and 9.8% of Clint ratio, respectively; P < 0.001). These findings should be useful for predicting the phenotype profiles of CYP2C9 in Chinese Han population, comparing the functional results of these alleles accurately, and finally optimizing pharmacotherapy of drug treatment.
引用
收藏
页数:6
相关论文
共 28 条
[1]   CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population [J].
Allabi, AC ;
Gala, JL ;
Horsmans, Y .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (11) :779-786
[2]   Discovery of new potentially defective alleles of human CYP2C9 [J].
Blaisdell, J ;
Jorge-Nebert, LF ;
Coulter, S ;
Ferguson, SS ;
Lee, SJ ;
Chanas, B ;
Xi, T ;
Mohrenweiser, H ;
Ghanayem, B ;
Goldstein, JA .
PHARMACOGENETICS, 2004, 14 (08) :527-537
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[5]   In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population [J].
Dai, Da-peng ;
Wang, Yu-han ;
Wang, Shuang-hu ;
Geng, Pei-wu ;
Hu, Li-ming ;
Hu, Guo-xin ;
Cai, Jian-ping .
ACTA PHARMACOLOGICA SINICA, 2013, 34 (11) :1449-1456
[6]  
GOTOH O, 1992, J BIOL CHEM, V267, P83
[7]   Catalytic activities of human cytochrome P4502C9*1, 2C9*3 and 2C9*13 [J].
Guo, Y ;
Wang, Y ;
Si, D ;
Fawcett, PJ ;
Zhong, D ;
Zhou, H .
XENOBIOTICA, 2005, 35 (09) :853-861
[8]   Functional characterization of three human cytochrome P450 2E1 variants with amino acid substitutions [J].
Hanioka, N ;
Tanaka-Kagawa, T ;
Miyata, Y ;
Matsushima, E ;
Makino, Y ;
Ohno, A ;
Yoda, R ;
Jinno, H ;
Ando, M .
XENOBIOTICA, 2003, 33 (06) :575-586
[9]   Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes [J].
Hemeryck, A ;
De Vriendt, C ;
Belpaire, FM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 54 (12) :947-951
[10]   Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].
Higashi, MK ;
Veenstra, DL ;
Kondo, LML ;
Wittkowsky, AK ;
Srinouanprachanh, SL ;
Farin, FM ;
Rettie, AE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698